A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
← catalyst calendarNCT07196644 · readout ≤ 1,595 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
38
Countries
Israel, Japan, South Korea +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-01 | actual | When the study began enrolling |
| Primary completion | Dec 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumors Harboring MET Amplification
Intervention
- Drug: Telisotuzumab Adizutecan
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AE)s
measured Up to 61.5 Months
Confirmed Objective Response (OR) as Assessed by Independent Central Review (ICR)
measured Up to 36 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed